Biochemical mechanisms of neurodegeneration in Parkinson's disease: Mitochondrial dysfunction, oxidative stress and glutamatergic excitotoxicity

Frontiers in Parkinson's Disease Research

Volumn , Issue , 2012, Pages 51-92

  Latini, Alexandra ^a   De Bem, Andreza F ^a   Raisman Vozari, Rita ^b   Tasca, Carla I ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

Author keywords

Glutamatergic excitotoxicity; Mitochondrial dysfunction; Oxidative stress; Parkinson's disease

Indexed keywords

EID: 84895227537     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (295)

1. Hastings, TG. The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease. J Bioenerg Biomembr, 2009 (41), 469-72.
2. Abou-Sleiman, PM; Muqit, MMK; Wood, NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nature Reviews Neuroscience, 2006 (7), 207-19.
3. Ziemssen, T; Reichmann, H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord, 2007 (13), 323-32.
4. Drechsel, DA; Patel, M. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic Biol Med, 2008 (44), 1873-86.
5. Spillantini, MG; Schmidt, ML; Lee, VM; Trojanowski, JQ; Jakes, R; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997 (388), 839-40.
6. Bernheimer, H; Birkmayer, W; Hornykiewicz, O; Jellinger, K; Seitelberger, F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci, 1973 (20), 415-55.
7. Abeliovich, A; Flint Beal, M. Parkinsonism genes: culprits and clues. J Neurochem, 2006 (99), 1062-72.
8. Tsang, AH; Chung, KK. Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta, 2009 (1792), 643-50.
9. Rodriguez, MC; Obeso, JA; Olanow, CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol, 1998 (44), S175-88.
10. Mattson, MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol, 2000 (1), 120-9.
11. Tansey, MG; McCoy, MK; Frank-Cannon, TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol, 2007 (208), 1-25.
12. Zhou, C; Huang, Y; Przedborski, S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci, 2008 (1147), 93-104.
13. Nicholls, DG; Ferguson, SJ. Bioenergetics 3. London: Academic Press; 2002.
14. Boveris, A; Cadenas, E; Stoppani, AO. Role of ubiquinone in the mitochondrial generation of hydrogen peroxide. Biochem J, 1976 (156), 435-44.
15. Chen, Q; Vazquez, EJ; Moghaddas, S; Hoppel, CL; Lesnefsky, EJ. Production of reactive oxygen species by mitochondria: central role of complex III. J Biol Chem, 2003 (278), 36027-31.
16. Turrens, JF. Superoxide production by the mitochondrial respiratory chain. Biosci Rep, 1997 (17), 3-8.
17. Turrens, JF; Boveris, A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J, 1980 (191), 421-7.
18. Zhang, Y; Marcillat, O; Giulivi, C; Ernster, L; Davies, KJ. The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J Biol Chem, 1990 (265), 16330-6.
19. Hausladen, A; Fridovich, I. Superoxide and peroxynitrite inactivate aconitases, but nitric oxide does not. J Biol Chem, 1994 (269), 29405-8.
20. Bandy, B; Davison, AJ. Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging? Free Radic Biol Med, 1990 (8), 523-39.
21. Chinopoulos, C; Adam-Vizi, V. Mitochondria deficient in complex I activity are depolarized by hydrogen peroxide in nerve terminals: relevance to Parkinson's disease. J Neurochem, 2001 (76), 302-6.
22. Vieira, HL; Belzacq, AS; Haouzi, D; Bernassola, F; Cohen, I; Jacotot, E; Ferri, KF; El Hamel, C; Bartle, LM; Melino, G; Brenner, C; Goldmacher, V; Kroemer, G. The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4-hydroxynonenal. Oncogene, 2001 (20), 4305-16.
23. Kagan, VE; Tyurin, VA; Jiang, J; Tyurina, YY; Ritov, VB; Amoscato, AA; Osipov, AN; Belikova, NA; Kapralov, AA; Kini, V; Vlasova, II; Zhao, Q; Zou, M; Di, P; Svistunenko, DA; Kurnikov, IV; Borisenko, GG. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat Chem Biol, 2005 (1), 223-32.
24. Basova, LV; Kurnikov, IV; Wang, L; Ritov, VB; Belikova, NA; Vlasova, II; Pacheco, AA; Winnica, DE; Peterson, J; Bayir, H; Waldeck, DH; Kagan, VE. Cardiolipin switch in mitochondria: shutting off the reduction of cytochrome c and turning on the peroxidase activity. Biochemistry, 2007 (46), 3423-34.
25. Westermann, B. Molecular machinery of mitochondrial fusion and fission. J Biol Chem, 2008 (283), 13501-5.
26. Knott, AB; Perkins, G; Schwarzenbacher, R; Bossy-Wetzel, E. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci, 2008 (9), 505-18.
27. Onyango, IG. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Neurochem Res, 2008 (33), 589-97.
28. Schapira, AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol, 2008 (7), 97-109.
29. Schapira, AH; Cooper, JM; Dexter, D; Jenner, P; Clark, JB; Marsden, CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet, 1989 (1), 1269.
30. Mizuno, Y; Ohta, S; Tanaka, M; Takamiya, S; Suzuki, K; Sato, T; Oya, H; Ozawa, T; Kagawa, Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun, 1989 (163), 1450-5.
31. Parker, WD, Jr.; Boyson, SJ; Parks, JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol, 1989 (26), 719-23.
32. Parker, WD, Jr.; Parks, JK; Swerdlow, RH. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res, 2008 (1189), 215-8.
33. Hattori, N; Tanaka, M; Ozawa, T; Mizuno, Y. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann Neurol, 1991 (30), 563-71.
34. Keeney, PM; Xie, J; Capaldi, RA; Bennett, JP, Jr. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci, 2006 (26), 5256-64.
35. Bender, A; Krishnan, KJ; Morris, CM; Taylor, GA; Reeve, AK; Perry, RH; Jaros, E; Hersheson, JS; Betts, J; Klopstock, T; Taylor, RW; Turnbull, DM. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet, 2006 (38), 515-7.
36. Chan, CS; Gertler, TS; Surmeier, DJ. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov Disord, (25), S63-S70.
37. Hu, MT; Taylor-Robinson, SD; Chaudhuri, KR; Bell, JD; Labbe, C; Cunningham, VJ; Koepp, MJ; Hammers, A; Morris, RG; Turjanski, N; Brooks, DJ. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain, 2000 (123 (Pt 2)), 340-52.
38. Rango, M; Bonifati, C; Bresolin, N. Parkinson's disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study. J Cereb Blood Flow Metab, 2006 (26), 283-90.
39. Bowen, BC; Block, RE; Sanchez-Ramos, J; Pattany, PM; Lampman, DA; Murdoch, JB; Quencer, RM. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol, 1995 (16), 61-8.
40. Hattingen, E; Magerkurth, J; Pilatus, U; Mozer, A; Seifried, C; Steinmetz, H; Zanella, F; Hilker, R. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain, 2009 (132), 3285-97.
41. Krige, D; Carroll, MT; Cooper, JM; Marsden, CD; Schapira, AH. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol, 1992 (32), 782-8.
42. Bindoff, LA; Birch-Machin, M; Cartlidge, NE; Parker, WD, Jr.; Turnbull, DM. Mitochondrial function in Parkinson's disease. Lancet, 1989 (2), 49.
43. Mann, VM; Cooper, JM; Daniel, SE; Srai, K; Jenner, P; Marsden, CD; Schapira, AH. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol, 1994 (36), 876-81.
44. Mann, VM; Cooper, JM; Krige, D; Daniel, SE; Schapira, AH; Marsden, CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain, 1992 (115 (Pt 2)), 333-42.
45. Janetzky, B; Hauck, S; Youdim, MB; Riederer, P; Jellinger, K; Pantucek, F; Zochling, R; Boissl, KW; Reichmann, H. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett, 1994 (169), 126-8.
46. Haas, RH; Nasirian, F; Nakano, K; Ward, D; Pay, M; Hill, R; Shults, CW. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol, 1995 (37), 714-22.
47. Swerdlow, RH; Parks, JK; Miller, SW; Tuttle, JB; Trimmer, PA; Sheehan, JP; Bennett, JP, Jr.; Davis, RE; Parker, WD, Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol, 1996 (40), 663-71.
48. Gu, M; Cooper, JM; Taanman, JW; Schapira, AH. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol, 1998 (44), 177-86.
49. Ferrer, I. Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects. Prog Neurobiol, 2009 (88), 89-103.
50. Reichmann, H; Janetzky, B; Bischof, F; Seibel, P; Schols, L; Kuhn, W; Przuntek, H. Unaltered respiratory chain enzyme activity and mitochondrial DNA in skeletal muscle from patients with idiopathic Parkinson's syndrome. Eur Neurol, 1994 (34), 263-7.
51. Blin, O; Desnuelle, C; Rascol, O; Borg, M; Peyro Saint Paul, H; Azulay, JP; Bille, F; Figarella, D; Coulom, F; Pellissier, JF; et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J Neurol Sci, 1994 (125), 95-101.
52. Shults, CW; Oakes, D; Kieburtz, K; Beal, MF; Haas, R; Plumb, S; Juncos, JL; Nutt, J; Shoulson, I; Carter, J; Kompoliti, K; Perlmutter, JS; Reich, S; Stern, M; Watts, RL; Kurlan, R; Molho, E; Harrison, M; Lew, M. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol, 2002 (59), 1541-50.
53. Storch, A; Jost, WH; Vieregge, P; Spiegel, J; Greulich, W; Durner, J; Muller, T; Kupsch, A; Henningsen, H; Oertel, WH; Fuchs, G; Kuhn, W; Niklowitz, P; Koch, R; Herting, B; Reichmann, H. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol, 2007 (64), 938-44.
54. Winkler-Stuck, K; Wiedemann, FR; Wallesch, CW; Kunz, WS. Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. J Neurol Sci, 2004 (220), 41-8.
55. Shults, CW; Haas, RH; Passov, D; Beal, MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol, 1997 (42), 261-4.
56. Matsubara, T; Azums, T; Yoshids, S; Yamegami, T. Serum coenzyme Q-10 level in Parkinson syndrome. In: Folkers K, Littarru GP, Yamagami T, editors. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier Science 1991. p. 159-66.
57. Hargreaves, IP; Lane, A; Sleiman, PM. The coenzyme Q10 status of the brain regions of Parkinson's disease patients. Neurosci Lett, 2008 (447), 17-9.
58. Yoshino, H; Nakagawa-Hattori, Y; Kondo, T; Mizuno, Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm Park Dis Dement Sect, 1992 (4), 27-34.
59. Benecke, R; Strumper, P; Weiss, H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain, 1993 (116 (Pt 6)), 1451-63.
60. Mizuno, Y; Matuda, S; Yoshino, H; Mori, H; Hattori, N; Ikebe, S. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol, 1994 (35), 204-10.
61. Polymeropoulos, MH; Lavedan, C; Leroy, E; Ide, SE; Dehejia, A; Dutra, A; Pike, B; Root, H; Rubenstein, J; Boyer, R; Stenroos, ES; Chandrasekharappa, S; Athanassiadou, A; Papapetropoulos, T; Johnson, WG; Lazzarini, AM; Duvoisin, RC; Di Iorio, G; Golbe, LI; Nussbaum, RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 1997 (276), 2045-7.
62. Kruger, R; Kuhn, W; Muller, T; Woitalla, D; Graeber, M; Kosel, S; Przuntek, H; Epplen, JT; Schols, L; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet, 1998 (18), 106-8.
63. Zarranz, JJ; Alegre, J; Gomez-Esteban, JC; Lezcano, E; Ros, R; Ampuero, I; Vidal, L; Hoenicka, J; Rodriguez, O; Atares, B; Llorens, V; Gomez Tortosa, E; del Ser, T; Munoz, DG; de Yebenes, JG. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol, 2004 (55), 164-73.
64. Chartier-Harlin, MC; Kachergus, J; Roumier, C; Mouroux, V; Douay, X; Lincoln, S; Levecque, C; Larvor, L; Andrieux, J; Hulihan, M; Waucquier, N; Defebvre, L; Amouyel, P; Farrer, M; Destee, A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 2004 (364), 1167-9.
65. Ibanez, P; Bonnet, AM; Debarges, B; Lohmann, E; Tison, F; Pollak, P; Agid, Y; Durr, A; Brice, A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet, 2004 (364), 1169-71.
66. Nishioka, K; Hayashi, S; Farrer, MJ; Singleton, AB; Yoshino, H; Imai, H; Kitami, T; Sato, K; Kuroda, R; Tomiyama, H; Mizoguchi, K; Murata, M; Toda, T; Imoto, I; Inazawa, J; Mizuno, Y; Hattori, N. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol, 2006 (59), 298-309.
67. Farrer, M; Kachergus, J; Forno, L; Lincoln, S; Wang, DS; Hulihan, M; Maraganore, D; Gwinn-Hardy, K; Wszolek, Z; Dickson, D; Langston, JW. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol, 2004 (55), 174-9.
68. Singleton, AB; Farrer, M; Johnson, J; Singleton, A; Hague, S; Kachergus, J; Hulihan, M; Peuralinna, T; Dutra, A; Nussbaum, R; Lincoln, S; Crawley, A; Hanson, M; Maraganore, D; Adler, C; Cookson, MR; Muenter, M; Baptista, M; Miller, D; Blancato, J; Hardy, J; Gwinn-Hardy, K. alpha-Synuclein locus triplication causes Parkinson's disease. Science, 2003 (302), 841.
69. Golbe, LI; Di Iorio, G; Bonavita, V; Miller, DC; Duvoisin, RC. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol, 1990 (27), 276-82.
70. Duda, JE; Lee, VM; Trojanowski, JQ. Neuropathology of synuclein aggregates. J Neurosci Res, 2000 (61), 121-7.
71. Danielson, SR; Held, JM; Schilling, B; Oo, M; Gibson, BW; Andersen, JK. Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. Anal Chem, 2009 (81), 7823-8.
72. Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci, 2001 (2), 492-501.
73. Devi, L; Raghavendran, V; Prabhu, BM; Avadhani, NG; Anandatheerthavarada, HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem, 2008 (283), 9089-100.
74. Cole, NB; Dieuliis, D; Leo, P; Mitchell, DC; Nussbaum, RL. Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp Cell Res, 2008 (314), 2076-89.
75. Shavali, S; Brown-Borg, HM; Ebadi, M; Porter, J. Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci Lett, 2008 (439), 125-8.
76. Darios, F; Ruiperez, V; Lopez, I; Villanueva, J; Gutierrez, LM; Davletov, B. Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis. EMBO Rep, (11), 528-33.
77. Chandra, S; Gallardo, G; Fernandez-Chacon, R; Schluter, OM; Sudhof, TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell, 2005 (123), 383-96.
78. Ellis, CE; Murphy, EJ; Mitchell, DC; Golovko, MY; Scaglia, F; Barcelo-Coblijn, GC; Nussbaum, RL. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol Cell Biol, 2005 (25), 10190-201.
79. Martin, LJ; Pan, Y; Price, AC; Sterling, W; Copeland, NG; Jenkins, NA; Price, DL; Lee, MK. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci, 2006 (26), 41-50.
80. Poon, HF; Frasier, M; Shreve, N; Calabrese, V; Wolozin, B; Butterfield, DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease. Neurobiol Dis, 2005 (18), 492-8.
81. Loeb, V; Yakunin, E; Saada, A; Sharon, R. The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. J Biol Chem, (285), 7334-43.
82. Parihar, MS; Parihar, A; Fujita, M; Hashimoto, M; Ghafourifar, P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci, 2008 (65), 1272-84.
83. Abbas, N; Lucking, CB; Ricard, S; Durr, A; Bonifati, V; De Michele, G; Bouley, S; Vaughan, JR; Gasser, T; Marconi, R; Broussolle, E; Brefel-Courbon, C; Harhangi, BS; Oostra, BA; Fabrizio, E; Bohme, GA; Pradier, L; Wood, NW; Filla, A; Meco, G; Denefle, P; Agid, Y; Brice, A. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet, 1999 (8), 567-74.
84. Lucking, CB; Durr, A; Bonifati, V; Vaughan, J; De Michele, G; Gasser, T; Harhangi, BS; Meco, G; Denefle, P; Wood, NW; Agid, Y; Brice, A. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med, 2000 (342), 1560-7.
85. Yamamura, Y; Sobue, I; Ando, K; Iida, M; Yanagi, T. Paralysis agitans of early onset with marked diurnal fluctuation of symptoms. Neurology, 1973 (23), 239-44.
86. Muftuoglu, M; Elibol, B; Dalmizrak, O; Ercan, A; Kulaksiz, G; Ogus, H; Dalkara, T; Ozer, N. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord, 2004 (19), 544-8.
87. Stichel, CC; Augustin, M; Kuhn, K; Zhu, XR; Engels, P; Ullmer, C; Lubbert, H. Parkin expression in the adult mouse brain. Eur J Neurosci, 2000 (12), 4181-94.
88. Kubo, SI; Kitami, T; Noda, S; Shimura, H; Uchiyama, Y; Asakawa, S; Minoshima, S; Shimizu, N; Mizuno, Y; Hattori, N. Parkin is associated with cellular vesicles. J Neurochem, 2001 (78), 42-54.
89. Shimura, H; Hattori, N; Kubo, S; Yoshikawa, M; Kitada, T; Matsumine, H; Asakawa, S; Minoshima, S; Yamamura, Y; Shimizu, N; Mizuno, Y. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol, 1999 (45), 668-72.
90. Kahle, PJ; Haass, C. How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep, 2004 (5), 681-5.
91. Greene, JC; Whitworth, AJ; Kuo, I; Andrews, LA; Feany, MB; Pallanck, LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A, 2003 (100), 4078-83.
92. Whitworth, AJ; Theodore, DA; Greene, JC; Benes, H; Wes, PD; Pallanck, LJ. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci U S A, 2005 (102), 8024-9.
93. Palacino, JJ; Sagi, D; Goldberg, MS; Krauss, S; Motz, C; Wacker, M; Klose, J; Shen, J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem, 2004 (279), 18614-22.
94. Yao, D; Gu, Z; Nakamura, T; Shi, ZQ; Ma, Y; Gaston, B; Palmer, LA; Rockenstein, EM; Zhang, Z; Masliah, E; Uehara, T; Lipton, SA. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A, 2004 (101), 10810-4.
95. Chung, KK; Thomas, B; Li, X; Pletnikova, O; Troncoso, JC; Marsh, L; Dawson, VL; Dawson, TM. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science, 2004 (304), 1328-31.
96. Darios, F; Corti, O; Lucking, CB; Hampe, C; Muriel, MP; Abbas, N; Gu, WJ; Hirsch, EC; Rooney, T; Ruberg, M; Brice, A. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet, 2003 (12), 517-26.
97. Sleven, H; Gibbs, JE; Heales, S; Thom, M; Cock, HR. Depletion of reduced glutathione precedes inactivation of mitochondrial enzymes following limbic status epilepticus in the rat hippocampus. Neurochem Int, 2006 (48), 75-82.
98. Kuroda, Y; Mitsui, T; Kunishige, M; Shono, M; Akaike, M; Azuma, H; Matsumoto, T. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet, 2006 (15), 883-95.
99. Zhou, C; Huang, Y; Shao, Y; May, J; Prou, D; Perier, C; Dauer, W; Schon, EA; Przedborski, S. The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci U S A, 2008 (105), 12022-7.
100. Liu, W; Vives-Bauza, C; Acin-Perez, R; Yamamoto, A; Tan, Y; Li, Y; Magrane, J; Stavarache, MA; Shaffer, S; Chang, S; Kaplitt, MG; Huang, XY; Beal, MF; Manfredi, G; Li, C. PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS One, 2009 (4), e4597.
101. Pridgeon, JW; Olzmann, JA; Chin, LS; Li, L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol, 2007 (5), e172.
102. Brooks, J; Ding, J; Simon-Sanchez, J; Paisan-Ruiz, C; Singleton, AB; Scholz, SW. Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available cases and control. J Med Genet, 2009 (46), 375-81.
103. Valente, EM; Salvi, S; Ialongo, T; Marongiu, R; Elia, AE; Caputo, V; Romito, L; Albanese, A; Dallapiccola, B; Bentivoglio, AR. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol, 2004 (56), 336-41.
104. Gandhi, S; Muqit, MM; Stanyer, L; Healy, DG; Abou-Sleiman, PM; Hargreaves, I; Heales, S; Ganguly, M; Parsons, L; Lees, AJ; Latchman, DS; Holton, JL; Wood, NW; Revesz, T. PINK1 protein in normal human brain and Parkinson's disease. Brain, 2006 (129), 1720-31.
105. Hoepken, HH; Gispert, S; Morales, B; Wingerter, O; Del Turco, D; Mulsch, A; Nussbaum, RL; Muller, K; Drose, S; Brandt, U; Deller, T; Wirth, B; Kudin, AP; Kunz, WS; Auburger, G. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis, 2007 (25), 401-11.
106. Clark, IE; Dodson, MW; Jiang, C; Cao, JH; Huh, JR; Seol, JH; Yoo, SJ; Hay, BA; Guo, M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature, 2006 (441), 1162-6.
107. Morais, VA; Verstreken, P; Roethig, A; Smet, J; Snellinx, A; Vanbrabant, M; Haddad, D; Frezza, C; Mandemakers, W; Vogt-Weisenhorn, D; Van Coster, R; Wurst, W; Scorrano, L; De Strooper, B. Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol Med, 2009 (1), 99-111.
108. Exner, N; Treske, B; Paquet, D; Holmstrom, K; Schiesling, C; Gispert, S; Carballo-Carbajal, I; Berg, D; Hoepken, HH; Gasser, T; Kruger, R; Winklhofer, KF; Vogel, F; Reichert, AS; Auburger, G; Kahle, PJ; Schmid, B; Haass, C. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci, 2007 (27), 12413-8.
109. Park, J; Kim, Y; Chung, J. Mitochondrial dysfunction and Parkinson's disease genes: insights from Drosophila. Dis Model Mech, 2009 (2), 336-40.
110. Yang, Y; Gehrke, S; Imai, Y; Huang, Z; Ouyang, Y; Wang, JW; Yang, L; Beal, MF; Vogel, H; Lu, B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A, 2006 (103), 10793-8.
111. Thomas, KJ; Cookson, MR. The role of PTEN-induced kinase 1 in mitochondrial dysfunction and dynamics. Int J Biochem Cell Biol, 2009 (41), 2025-35.
112. Yang, Y; Ouyang, Y; Yang, L; Beal, MF; McQuibban, A; Vogel, H; Lu, B. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci U S A, 2008 (105), 7070-5.
113. Poole, AC; Thomas, RE; Andrews, LA; McBride, HM; Whitworth, AJ; Pallanck, LJ. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci U S A, 2008 (105), 1638-43.
114. Geisler, S; Holmstrom, KM; Skujat, D; Fiesel, FC; Rothfuss, OC; Kahle, PJ; Springer, W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol, (12), 119-31.
115. Vives-Bauza, C; Zhou, C; Huang, Y; Cui, M; de Vries, RL; Kim, J; May, J; Tocilescu, MA; Liu, W; Ko, HS; Magrane, J; Moore, DJ; Dawson, VL; Grailhe, R; Dawson, TM; Li, C; Tieu, K; Przedborski, S. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A, (107), 378-83.
116. Poole, AC; Thomas, RE; Yu, S; Vincow, ES; Pallanck, L. The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway. PLoS One, (5), e10054.
117. Bonifati, V; Rizzu, P; Squitieri, F; Krieger, E; Vanacore, N; van Swieten, JC; Brice, A; van Duijn, CM; Oostra, B; Meco, G; Heutink, P. DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci, 2003 (24), 159-60.
118. Bonifati, V; Rizzu, P; van Baren, MJ; Schaap, O; Breedveld, GJ; Krieger, E; Dekker, MC; Squitieri, F; Ibanez, P; Joosse, M; van Dongen, JW; Vanacore, N; van Swieten, JC; Brice, A; Meco, G; van Duijn, CM; Oostra, BA; Heutink, P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 2003 (299), 256-9.
119. Hague, S; Rogaeva, E; Hernandez, D; Gulick, C; Singleton, A; Hanson, M; Johnson, J; Weiser, R; Gallardo, M; Ravina, B; Gwinn-Hardy, K; Crawley, A; St George-Hyslop, PH; Lang, AE; Heutink, P; Bonifati, V; Hardy, J. Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol, 2003 (54), 271-4.
120. Cookson, MR. Pathways to Parkinsonism. Neuron, 2003 (37), 7-10.
121. Canet-Aviles, RM; Wilson, MA; Miller, DW; Ahmad, R; McLendon, C; Bandyopadhyay, S; Baptista, MJ; Ringe, D; Petsko, GA; Cookson, MR. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A, 2004 (101), 9103-8.
122. Blackinton, J; Lakshminarasimhan, M; Thomas, KJ; Ahmad, R; Greggio, E; Raza, AS; Cookson, MR; Wilson, MA. Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. J Biol Chem, 2009 (284), 6476-85.
123. Taira, T; Saito, Y; Niki, T; Iguchi-Ariga, SM; Takahashi, K; Ariga, H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep, 2004 (5), 213-8.
124. Bandopadhyay, R; Kingsbury, AE; Cookson, MR; Reid, AR; Evans, IM; Hope, AD; Pittman, AM; Lashley, T; Canet-Aviles, R; Miller, DW; McLendon, C; Strand, C; Leonard, AJ; Abou-Sleiman, PM; Healy, DG; Ariga, H; Wood, NW; de Silva, R; Revesz, T; Hardy, JA; Lees, AJ. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain, 2004 (127), 420-30.
125. Choi, J; Sullards, MC; Olzmann, JA; Rees, HD; Weintraub, ST; Bostwick, DE; Gearing, M; Levey, AI; Chin, LS; Li, L. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem, 2006 (281), 10816-24.
126. Betarbet, R; Canet-Aviles, RM; Sherer, TB; Mastroberardino, PG; McLendon, C; Kim, JH; Lund, S; Na, HM; Taylor, G; Bence, NF; Kopito, R; Seo, BB; Yagi, T; Yagi, A; Klinefelter, G; Cookson, MR; Greenamyre, JT. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis, 2006 (22), 404-20.
127. Andres-Mateos, E; Perier, C; Zhang, L; Blanchard-Fillion, B; Greco, TM; Thomas, B; Ko, HS; Sasaki, M; Ischiropoulos, H; Przedborski, S; Dawson, TM; Dawson, VL. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A, 2007 (104), 14807-12.
128. Zhang, L; Shimoji, M; Thomas, B; Moore, DJ; Yu, SW; Marupudi, NI; Torp, R; Torgner, IA; Ottersen, OP; Dawson, TM; Dawson, VL. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet, 2005 (14), 2063-73.
129. van der Brug, MP; Blackinton, J; Chandran, J; Hao, LY; Lal, A; Mazan-Mamczarz, K; Martindale, J; Xie, C; Ahmad, R; Thomas, KJ; Beilina, A; Gibbs, JR; Ding, J; Myers, AJ; Zhan, M; Cai, H; Bonini, NM; Gorospe, M; Cookson, MR. RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc Natl Acad Sci U S A, 2008 (105), 10244-9.
130. Krebiehl, G; Ruckerbauer, S; Burbulla, LF; Kieper, N; Maurer, B; Waak, J; Wolburg, H; Gizatullina, Z; Gellerich, FN; Woitalla, D; Riess, O; Kahle, PJ; Proikas-Cezanne, T; Kruger, R. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS One, (5), e9367.
131. Moore, DJ; Zhang, L; Troncoso, J; Lee, MK; Hattori, N; Mizuno, Y; Dawson, TM; Dawson, VL. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet, 2005 (14), 71-84.
132. Tang, B; Xiong, H; Sun, P; Zhang, Y; Wang, D; Hu, Z; Zhu, Z; Ma, H; Pan, Q; Xia, JH; Xia, K; Zhang, Z. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet, 2006 (15), 1816-25.
133. Xiong, H; Wang, D; Chen, L; Choo, YS; Ma, H; Tang, C; Xia, K; Jiang, W; Ronai, Z; Zhuang, X; Zhang, Z. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest, 2009 (119), 650-60.
134. Mata, IF; Wedemeyer, WJ; Farrer, MJ; Taylor, JP; Gallo, KA. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci, 2006 (29), 286-93.
135. Zimprich, A; Biskup, S; Leitner, P; Lichtner, P; Farrer, M; Lincoln, S; Kachergus, J; Hulihan, M; Uitti, RJ; Calne, DB; Stoessl, AJ; Pfeiffer, RF; Patenge, N; Carbajal, IC; Vieregge, P; Asmus, F; Muller-Myhsok, B; Dickson, DW; Meitinger, T; Strom, TM; Wszolek, ZK; Gasser, T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 2004 (44), 601-7.
136. Paisan-Ruiz, C; Jain, S; Evans, EW; Gilks, WP; Simon, J; van der Brug, M; Lopez de Munain, A; Aparicio, S; Gil, AM; Khan, N; Johnson, J; Martinez, JR; Nicholl, D; Carrera, IM; Pena, AS; de Silva, R; Lees, A; Marti-Masso, JF; Perez-Tur, J; Wood, NW; Singleton, AB. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 2004 (44), 595-600.
137. Paisan-Ruiz, C; Saenz, A; Lopez de Munain, A; Marti, I; Martinez Gil, A; Marti-Masso, JF; Perez-Tur, J. Familial Parkinson's disease: clinical and genetic analysis of four Basque families. Ann Neurol, 2005 (57), 365-72.
138. Wszolek, ZK; Vieregge, P; Uitti, RJ; Gasser, T; Yasuhara, O; McGeer, P; Berry, K; Calne, DB; Vingerhoets, FJ; Klein, C; Pfeiffer, RF. German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia-Longitudinal observations. Parkinsonism Relat Disord, 1997 (3), 125-39.
139. Biskup, S; Moore, DJ; Celsi, F; Higashi, S; West, AB; Andrabi, SA; Kurkinen, K; Yu, SW; Savitt, JM; Waldvogel, HJ; Faull, RL; Emson, PC; Torp, R; Ottersen, OP; Dawson, TM; Dawson, VL. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol, 2006 (60), 557-69.
140. West, AB; Moore, DJ; Biskup, S; Bugayenko, A; Smith, WW; Ross, CA; Dawson, VL; Dawson, TM. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A, 2005 (102), 16842-7.
141. Gloeckner, CJ; Kinkl, N; Schumacher, A; Braun, RJ; O'Neill, E; Meitinger, T; Kolch, W; Prokisch, H; Ueffing, M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet, 2006 (15), 223-32.
142. Ito, G; Okai, T; Fujino, G; Takeda, K; Ichijo, H; Katada, T; Iwatsubo, T. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry, 2007 (46), 1380-8.
143. Smith, WW; Pei, Z; Jiang, H; Moore, DJ; Liang, Y; West, AB; Dawson, VL; Dawson, TM; Ross, CA. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A, 2005 (102), 18676-81.
144. Ng, CH; Mok, SZ; Koh, C; Ouyang, X; Fivaz, ML; Tan, EK; Dawson, VL; Dawson, TM; Yu, F; Lim, KL. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci, 2009 (29), 11257-62.
145. Saha, S; Guillily, MD; Ferree, A; Lanceta, J; Chan, D; Ghosh, J; Hsu, CH; Segal, L; Raghavan, K; Matsumoto, K; Hisamoto, N; Kuwahara, T; Iwatsubo, T; Moore, L; Goldstein, L; Cookson, M; Wolozin, B. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci, 2009 (29), 9210-8.
146. Strauss, KM; Martins, LM; Plun-Favreau, H; Marx, FP; Kautzmann, S; Berg, D; Gasser, T; Wszolek, Z; Muller, T; Bornemann, A; Wolburg, H; Downward, J; Riess, O; Schulz, JB; Kruger, R. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet, 2005 (14), 2099-111.
147. Kawamoto, Y; Kobayashi, Y; Suzuki, Y; Inoue, H; Tomimoto, H; Akiguchi, I; Budka, H; Martins, LM; Downward, J; Takahashi, R. Accumulation of HtrA2/Omi in neuronal and glial inclusions in brains with alpha-synucleinopathies. J Neuropathol Exp Neurol, 2008 (67), 984-93.
148. Hegde, R; Srinivasula, SM; Zhang, Z; Wassell, R; Mukattash, R; Cilenti, L; DuBois, G; Lazebnik, Y; Zervos, AS; Fernandes-Alnemri, T; Alnemri, ES. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem, 2002 (277), 432-8.
149. Suzuki, Y; Imai, Y; Nakayama, H; Takahashi, K; Takio, K; Takahashi, R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell, 2001 (8), 613-21.
150. Martins, LM; Turk, BE; Cowling, V; Borg, A; Jarrell, ET; Cantley, LC; Downward, J. Binding specificity and regulation of the serine protease and PDZ domains of HtrA2/Omi. J Biol Chem, 2003 (278), 49417-27.
151. Suzuki, Y; Takahashi-Niki, K; Akagi, T; Hashikawa, T; Takahashi, R. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ, 2004 (11), 208-16.
152. Martins, LM; Morrison, A; Klupsch, K; Fedele, V; Moisoi, N; Teismann, P; Abuin, A; Grau, E; Geppert, M; Livi, GP; Creasy, CL; Martin, A; Hargreaves, I; Heales, SJ; Okada, H; Brandner, S; Schulz, JB; Mak, T; Downward, J. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol, 2004 (24), 9848-62.
153. Kieper, N; Holmstrom, KM; Ciceri, D; Fiesel, FC; Wolburg, H; Ziviani, E; Whitworth, AJ; Martins, LM; Kahle, PJ; Kruger, R. Modulation of mitochondrial function and morphology by interaction of Omi/HtrA2 with the mitochondrial fusion factor OPA1. Exp Cell Res, (316), 1213-24.
154. Plun-Favreau, H; Klupsch, K; Moisoi, N; Gandhi, S; Kjaer, S; Frith, D; Harvey, K; Deas, E; Harvey, RJ; McDonald, N; Wood, NW; Martins, LM; Downward, J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol, 2007 (9), 1243-52.
155. Uversky, VN. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res, 2004 (318), 225-41.
156. Nicolaou, K; Pfefferkorn, J; Schuler, F; Roecker, A; Cao, G; Casida, J. Combinatorial synthesis of novel and potent inhibitors of NADH:ubiquinone oxidoreductase. Chem Biol, 2000 (7), 979-92.
157. Schuler, F; Casida, JE. Functional coupling of PSST and ND1 subunits in NADH:ubiquinone oxidoreductase established by photoaffinity labeling. Biochim Biophys Acta, 2001 (1506), 79-87.
158. Talpade, DJ; Greene, JG; Higgins, DS, Jr.; Greenamyre, JT. In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone. J Neurochem, 2000 (75), 2611-21.
159. Panov, A; Dikalov, S; Shalbuyeva, N; Taylor, G; Sherer, T; Greenamyre, JT. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem, 2005 (280), 42026-35.
160. Betarbet, R; Sherer, TB; MacKenzie, G; Garcia-Osuna, M; Panov, AV; Greenamyre, JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci, 2000 (3), 1301-6.
161. Sherer, TB; Kim, JH; Betarbet, R; Greenamyre, JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol, 2003 (179), 9-16.
162. Alam, M; Schmidt, WJ. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res, 2002 (136), 317-24.
163. Sherer, TB; Betarbet, R; Kim, JH; Greenamyre, JT. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett, 2003 (341), 87-90.
164. Betarbet, R; Sherer, TB; Greenamyre, JT. Animal models of Parkinson's disease. Bioessays, 2002 (24), 308-18.
165. Hoglinger, GU; Feger, J; Prigent, A; Michel, PP; Parain, K; Champy, P; Ruberg, M; Oertel, WH; Hirsch, EC. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem, 2003 (84), 491-502.
166. Sakka, N; Sawada, H; Izumi, Y; Kume, T; Katsuki, H; Kaneko, S; Shimohama, S; Akaike, A. Dopamine is involved in selectivity of dopaminergic neuronal death by rotenone. Neuroreport, 2003 (14), 2425-8.
167. Langston, JW; Ballard, P; Tetrud, JW; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 1983 (219), 979-80.
168. Chiba, K; Trevor, A; Castagnoli, N, Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun, 1984 (120), 574-8.
169. Heikkila, RE; Hess, A; Duvoisin, RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science, 1984 (224), 1451-3.
170. Nicklas, WJ; Vyas, I; Heikkila, RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci, 1985 (36), 2503-8.
171. Ramsay, RR; Dadgar, J; Trevor, A; Singer, TP. Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci, 1986 (39), 581-8.
172. Ramsay, RR; Singer, TP. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem, 1986 (261), 7585-7.
173. Davey, GP; Tipton, KF; Murphy, MP. Uptake and accumulation of 1-methyl-4-phenylpyridinium by rat liver mitochondria measured using an ion-selective electrode. Biochem J, 1992 (288 (Pt 2)), 439-43.
174. Hoppel, CL; Grinblatt, D; Kwok, HC; Arora, PK; Singh, MP; Sayre, LM. Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+), the neurotoxic metabolite of MPTP. Biochem Biophys Res Commun, 1987 (148), 684-93.
175. Schmidt, N; Ferger, B. Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm, 2001 (108), 1263-82.
176. Javitch, JA; D'Amato, RJ; Strittmatter, SM; Snyder, SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A, 1985 (82), 2173-7.
177. Cleeter, MW; Cooper, JM; Schapira, AH. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem, 1992 (58), 786-9.
178. Tieu, K; Perier, C; Caspersen, C; Teismann, P; Wu, DC; Yan, SD; Naini, A; Vila, M; Jackson-Lewis, V; Ramasamy, R; Przedborski, S. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest, 2003 (112), 892-901.
179. Danielson, SR; Andersen, JK. Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med, 2008 (44), 1787-94.
180. Dexter, DT; Carter, CJ; Wells, FR; Javoy-Agid, F; Agid, Y; Lees, A; Jenner, P; Marsden, CD. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem, 1989 (52), 381-9.
181. Zhang, J; Perry, G; Smith, MA; Robertson, D; Olson, SJ; Graham, DG; Montine, TJ. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol, 1999 (154), 1423-9.
182. Martin, HL; Teismann, P. Glutathione--a review on its role and significance in Parkinson's disease. FASEB J, 2009 (23), 3263-72.
183. Giasson, BI; Duda, JE; Murray, IV; Chen, Q; Souza, JM; Hurtig, HI; Ischiropoulos, H; Trojanowski, JQ; Lee, VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science, 2000 (290), 985-9.
184. Staal, RG; Mosharov, EV; Sulzer, D. Dopamine neurons release transmitter via a flickering fusion pore. Nat Neurosci, 2004 (7), 341-6.
185. Hastings, TG. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem, 1995 (64), 919-24.
186. Westlund, KN; Denney, RM; Rose, RM; Abell, CW. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience, 1988 (25), 439-56.
187. Chinta, SJ; Andersen, JK. Redox imbalance in Parkinson's disease. Biochim Biophys Acta, 2008 (1780), 1362-7.
188. Hastings, TG; Lewis, DA; Zigmond, MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A, 1996 (93), 1956-61.
189. Hastings, TG; Lewis, DA; Zigmond, MJ. Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv Exp Med Biol, 1996 (387), 97-106.
190. Caudle, WM; Richardson, JR; Wang, MZ; Taylor, TN; Guillot, TS; McCormack, AL; Colebrooke, RE; Di Monte, DA; Emson, PC; Miller, GW. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci, 2007 (27), 8138-48.
191. Aoyama, K; Suh, SW; Hamby, AM; Liu, J; Chan, WY; Chen, Y; Swanson, RA. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci, 2006 (9), 119-26.
192. Rabinovic, AD; Lewis, DA; Hastings, TG. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience, 2000 (101), 67-76.
193. Zecca, L; Zucca, FA; Wilms, H; Sulzer, D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci, 2003 (26), 578-80.
194. Spencer, JP; Jenner, P; Daniel, SE; Lees, AJ; Marsden, DC; Halliwell, B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem, 1998 (71), 2112-22.
195. Halliwell, B. Hypothesis: proteasomal dysfunction: a primary event in neurogeneration that leads to nitrative and oxidative stress and subsequent cell death. Ann N Y Acad Sci, 2002 (962), 182-94.
196. Kuzuhara, S; Mori, H; Izumiyama, N; Yoshimura, M; Ihara, Y. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol, 1988 (75), 345-53.
197. Kitada, T; Asakawa, S; Hattori, N; Matsumine, H; Yamamura, Y; Minoshima, S; Yokochi, M; Mizuno, Y; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 1998 (392), 605-8.
198. Braak, H; Braak, E. Pathoanatomy of Parkinson's disease. J Neurol, 2000 (247 Suppl 2), II3-10.
199. Xu, J; Kao, SY; Lee, FJ; Song, W; Jin, LW; Yankner, BA. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med, 2002 (8), 600-6.
200. Brongholi, K; Souza, DG; Bainy, AC; Dafre, AL; Tasca, CI. Oxygen-glucose deprivation decreases glutathione levels and glutamate uptake in rat hippocampal slices. Brain Res, 2006 (1083), 211-8.
201. Norris, EH; Giasson, BI; Ischiropoulos, H; Lee, VM. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem, 2003 (278), 27230-40.
202. Thomas, MP; Chartrand, K; Reynolds, A; Vitvitsky, V; Banerjee, R; Gendelman, HE. Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J Neurochem, 2007 (100), 503-19.
203. Uversky, VN; Li, J; Fink, AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem, 2001 (276), 44284-96.
204. Gotz, ME; Double, K; Gerlach, M; Youdim, MB; Riederer, P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci, 2004 (1012), 193-208.
205. Kaur, D; Yantiri, F; Rajagopalan, S; Kumar, J; Mo, JQ; Boonplueang, R; Viswanath, V; Jacobs, R; Yang, L; Beal, MF; DiMonte, D; Volitaskis, I; Ellerby, L; Cherny, RA; Bush, AI; Andersen, JK. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron, 2003 (37), 899-909.
206. Blandini, F; Nappi, G; Tassorelli, C; Martignoni, E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol, 2000 (62), 63-88.
207. Jenner, P. Presymptomatic detection of Parkinson's disease. J Neural Transm Suppl, 1993 (40), 23-36.
208. Jenner, P; Olanow, CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology, 1996 (47), S161-70.
209. Kish, SJ; Morito, C; Hornykiewicz, O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett, 1985 (58), 343-6.
210. Dauer, W; Przedborski, S. Parkinson's disease: mechanisms and models. Neuron, 2003 (39), 889-909.
211. Albin, RL; Makowiec, RL; Hollingsworth, ZR; Dure, LSt; Penney, JB; Young, AB. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience, 1992 (46), 35-48.
212. McGeorge, AJ; Faull, RL. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience, 1989 (29), 503-37.
213. Bonsi, P; Cuomo, D; Picconi, B; Sciamanna, G; Tscherter, A; Tolu, M; Bernardi, G; Calabresi, P; Pisani, A. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease. Amino Acids, 2007 (32), 189-95.
214. Tallaksen-Greene, SJ; Wiley, RG; Albin, RL. Localization of striatal excitatory amino acid binding site subtypes to striatonigral projection neurons. Brain Res, 1992 (594), 165-70.
215. Bernard, V; Bolam, JP. Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat: co-localization at synapses with the GluR2/3 subunit of the AMPA receptor. Eur J Neurosci, 1998 (10), 3721-36.
216. Fotuhi, M; Sharp, AH; Glatt, CE; Hwang, PM; von Krosigk, M; Snyder, SH; Dawson, TM. Differential localization of phosphoinositide-linked metabotropic glutamate receptor (mGluR1) and the inositol 1,4,5-trisphosphate receptor in rat brain. J Neurosci, 1993 (13), 2001-12.
217. Ohishi, H; Shigemoto, R; Nakanishi, S; Mizuno, N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience, 1993 (53), 1009-18.
218. Testa, CM; Standaert, DG; Young, AB; Penney, JB, Jr. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J Neurosci, 1994 (14), 3005-18.
219. Romano, C; Sesma, MA; McDonald, CT; O'Malley, K; Van den Pol, AN; Olney, JW. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol, 1995 (355), 455-69.
220. Naito, A; Kita, H. The cortico-nigral projection in the rat: an anterograde tracing study with biotinylated dextran amine. Brain Res, 1994 (637), 317-22.
221. Smith, Y; Charara, A; Parent, A. Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey. J Comp Neurol, 1996 (364), 231-53.
222. Bezard, E; Gross, CE. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol, 1998 (55), 93-116.
223. Chergui, K; Charlety, PJ; Akaoka, H; Saunier, CF; Brunet, JL; Buda, M; Svensson, TH; Chouvet, G. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci, 1993 (5), 137-44.
224. Christoffersen, CL; Meltzer, LT. Evidence for N-methyl-D-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: possible preferential role for N-methyl-D-aspartate receptors. Neuroscience, 1995 (67), 373-81.
225. Albers, DS; Weiss, SW; Iadarola, MJ; Standaert, DG. Immunohistochemical localization of N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits in the substantia nigra pars compacta of the rat. Neuroscience, 1999 (89), 209-20.
226. Kosinski, CM; Standaert, DG; Testa, CM; Penney, JB, Jr.; Young, AB. Expression of metabotropic glutamate receptor 1 isoforms in the substantia nigra pars compacta of the rat. Neuroscience, 1998 (86), 783-98.
227. Smith, Y; Parent, A. Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Res, 1988 (453), 353-6.
228. Kita, H; Kitai, ST. Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J Comp Neurol, 1987 (260), 435-52.
229. Parent, A; Hazrati, LN. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev, 1995 (20), 91-127.
230. Canteras, NS; Shammah-Lagnado, SJ; Silva, BA; Ricardo, JA. Afferent connections of the subthalamic nucleus: a combined retrograde and anterograde horseradish peroxidase study in the rat. Brain Res, 1990 (513), 43-59.
231. Hassani, OK; Francois, C; Yelnik, J; Feger, J. Evidence for a dopaminergic innervation of the subthalamic nucleus in the rat. Brain Res, 1997 (749), 88-94.
232. Cossette, M; Levesque, M; Parent, A. Extrastriatal dopaminergic innervation of human basal ganglia. Neurosci Res, 1999 (34), 51-4.
233. Hedreen, JC. Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus. J Comp Neurol, 1999 (409), 400-10.
234. Albin, RL; Young, AB; Penney, JB. The functional anatomy of basal ganglia disorders. Trends Neurosci, 1989 (12), 366-75.
235. Graybiel, AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci, 1990 (13), 244-54.
236. Gerfen, CR. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci, 1992 (15), 133-9.
237. Rubio, ME; Wenthold, RJ. Glutamate receptors are selectively targeted to postsynaptic sites in neurons. Neuron, 1997 (18), 939-50.
238. Ozawa, S; Kamiya, H; Tsuzuki, K. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol, 1998 (54), 581-618.
239. Monahan, D; Wenthold, R. Ionotropic glutamate receptors. Totowa, NJ: Humana Press; 1997.
240. McBain, CJ; Mayer, ML. N-methyl-D-aspartic acid receptor structure and function. Physiol Rev, 1994 (74), 723-60.
241. Bettler, B; Mulle, C. Review: neurotransmitter receptors. II. AMPA and kainate receptors. Neuropharmacology, 1995 (34), 123-39.
242. Madden, DR. The structure and function of glutamate receptor ion channels. Nat Rev Neurosci, 2002 (3), 91-101.
243. Pin, JP; Duvoisin, R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology, 1995 (34), 1-26.
244. Conn, PJ; Pin, JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol, 1997 (37), 205-37.
245. Greenamyre, JT; Porter, RH. Anatomy and physiology of glutamate in the CNS. Neurology, 1994 (44), S7-13.
246. Nicoletti, F; Bruno, V; Copani, A; Casabona, G; Knopfel, T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci, 1996 (19), 267-71.
247. Olney, JW. Glutamate-induced neuronal necrosis in the infant mouse hypothalamus. An electron microscopic study. J Neuropathol Exp Neurol, 1971 (30), 75-90.
248. Meldrum, B; Garthwaite, J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci, 1990 (11), 379-87.
249. Coyle, JT; Puttfarcken, P. Oxidative stress, glutamate, and neurodegenerative disorders. Science, 1993 (262), 689-95.
250. Kure, S; Tominaga, T; Yoshimoto, T; Tada, K; Narisawa, K. Glutamate triggers internucleosomal DNA cleavage in neuronal cells. Biochem Biophys Res Commun, 1991 (179), 39-45.
251. Mattson, MP; Chan, SL. Calcium orchestrates apoptosis. Nat Cell Biol, 2003 (5), 1041-3.
252. Mattson, MP. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal, 2006 (8), 1997-2006.
253. Molz, S; Decker, H; Dal-Cim, T; Cremonez, C; Cordova, FM; Leal, RB; Tasca, CI. Glutamate-induced toxicity in hippocampal slices involves apoptotic features and p38 MAPK signaling. Neurochem Res, 2008 (33), 27-36.
254. Schousboe, A; Waagepetersen, HS. Role of astrocytes in glutamate homeostasis: implications for excitotoxicity. Neurotox Res, 2005 (8), 221-5.
255. Danbolt, NC. Glutamate uptake. Prog Neurobiol, 2001 (65), 1-105.
256. Anderson, CM; Swanson, RA. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia, 2000 (32), 1-14.
257. Trotti, D; Danbolt, NC; Volterra, A. Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol Sci, 1998 (19), 328-34.
258. Bonde, C; Sarup, A; Schousboe, A; Gegelashvili, G; Zimmer, J; Noraberg, J. Neurotoxic and neuroprotective effects of the glutamate transporter inhibitor DL-threo-beta-benzyloxyaspartate (DL-TBOA) during physiological and ischemia-like conditions. Neurochem Int, 2003 (43), 371-80.
259. Featherstone, D. Intercellular glutamate signaling in the nervous system and beyond. ACS Chem Neurosci, 2010 (1), 4-12.
260. Murphy, TH; Miyamoto, M; Sastre, A; Schnaar, RL; Coyle, JT. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron, 1989 (2), 1547-58.
261. Choi, DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron, 1988 (1), 623-34.
262. Rothman, SM; Olney, JW. Glutamate and the pathophysiology of hypoxic--ischemic brain damage. Ann Neurol, 1986 (19), 105-11.
263. Meredith, GE; Totterdell, S; Beales, M; Meshul, CK. Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol, 2009 (219), 334-40.
264. Erecinska, M; Dagani, F. Relationships between the neuronal sodium/potassium pump and energy metabolism. Effects of K+, Na+, and adenosine triphosphate in isolated brain synaptosomes. J Gen Physiol, 1990 (95), 591-616.
265. Novelli, A; Reilly, JA; Lysko, PG; Henneberry, RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res, 1988 (451), 205-12.
266. Albin, RL; Greenamyre, JT. Alternative excitotoxic hypotheses. Neurology, 1992 (42), 733-8.
267. Beal, MF; Hyman, BT; Koroshetz, W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci, 1993 (16), 125-31.
268. Greene, JG; Greenamyre, JT. Bioenergetics and glutamate excitotoxicity. Prog Neurobiol, 1996 (48), 613-34.
269. Jones, S; Gibb, AJ. Functional NR2B- and NR2D-containing NMDA receptor channels in rat substantia nigra dopaminergic neurones. J Physiol, 2005 (569), 209-21.
270. Brothwell, SL; Barber, JL; Monaghan, DT; Jane, DE; Gibb, AJ; Jones, S. NR2B- and NR2D-containing synaptic NMDA receptors in developing rat substantia nigra pars compacta dopaminergic neurones. J Physiol, 2008 (586), 739-50.
271. Laurie, DJ; Seeburg, PH. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur J Pharmacol, 1994 (268), 335-45.
272. Chatha, BT; Bernard, V; Streit, P; Bolam, JP. Synaptic localization of ionotropic glutamate receptors in the rat substantia nigra. Neuroscience, 2000 (101), 1037-51.
273. Groenewegen, HJ; Berendse, HW. Connections of the subthalamic nucleus with ventral striatopallidal parts of the basal ganglia in the rat. J Comp Neurol, 1990 (294), 607-22.
274. Difazio, MC; Hollingsworth, Z; Young, AB; Penney, JB, Jr. Glutamate receptors in the substantia nigra of Parkinson's disease brains. Neurology, 1992 (42), 402-6.
275. Blandini, F; Porter, RH; Greenamyre, JT. Glutamate and Parkinson's disease. Mol Neurobiol, 1996 (12), 73-94.
276. Nafia, I; Re, DB; Masmejean, F; Melon, C; Kachidian, P; Kerkerian-Le Goff, L; Nieoullon, A; Had-Aissouni, L. Preferential vulnerability of mesencephalic dopamine neurons to glutamate transporter dysfunction. J Neurochem, 2008 (105), 484-96.
277. Izumi, Y; Yamamoto, N; Matsuo, T; Wakita, S; Takeuchi, H; Kume, T; Katsuki, H; Sawada, H; Akaike, A. Vulnerability to glutamate toxicity of dopaminergic neurons is dependent on endogenous dopamine and MAPK activation. J Neurochem, 2009 (110), 745-55.
278. Blandini, F; Nappi, G; Greenamyre, JT. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann Neurol, 2001 (49), 525-9.
279. Hallett, PJ; Standaert, DG. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther, 2004 (102), 155-74.
280. Parsons, CG; Danysz, W; Quack, G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect, 1998 (11), 523-69.
281. Chase, TN; Oh, JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol, 2000 (47), S122-9; discussion S9-30.
282. Rouse, ST; Marino, MJ; Bradley, SR; Awad, H; Wittmann, M; Conn, PJ. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther, 2000 (88), 427-35.
283. Bruno, V; Battaglia, G; Copani, A; D'Onofrio, M; Di Iorio, P; De Blasi, A; Melchiorri, D; Flor, PJ; Nicoletti, F. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab, 2001 (21), 1013-33.
284. Ossowska, K; Konieczny, J; Wardas, J; Golembiowska, K; Wolfarth, S; Pilc, A. The role of striatal metabotropic glutamate receptors in Parkinson's disease. Amino Acids, 2002 (23), 193-8.
285. Marino, MJ; Conn, JP. Modulation of the basal ganglia by metabotropic glutamate receptors: potential for novel therapeutics. Curr Drug Targets CNS Neurol Disord, 2002 (1), 239-50.
286. Gubellini, P; Pisani, A; Centonze, D; Bernardi, G; Calabresi, P. Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. Prog Neurobiol, 2004 (74), 271-300.
287. Dawson, L; Chadha, A; Megalou, M; Duty, S. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br J Pharmacol, 2000 (129), 541-6.
288. Murray, TK; Messenger, MJ; Ward, MA; Woodhouse, S; Osborne, DJ; Duty, S; O'Neill, MJ. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem Behav, 2002 (73), 455-66.
289. Battaglia, G; Busceti, CL; Pontarelli, F; Biagioni, F; Fornai, F; Paparelli, A; Bruno, V; Ruggieri, S; Nicoletti, F. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology, 2003 (45), 155-66.
290. MacInnes, N; Messenger, MJ; Duty, S. Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br J Pharmacol, 2004 (141), 15-22.
291. Ossowska, K; Konieczny, J; Wolfarth, S; Wieronska, J; Pilc, A. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology, 2001 (41), 413-20.
292. Breysse, N; Baunez, C; Spooren, W; Gasparini, F; Amalric, M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci, 2002 (22), 5669-78.
293. Battaglia, G; Busceti, CL; Molinaro, G; Biagioni, F; Storto, M; Fornai, F; Nicoletti, F; Bruno, V. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci, 2004 (24), 828-35.
294. Pisani, A; Calabresi, P; Centonze, D; Bernardi, G. Activation of group III metabotropic glutamate receptors depresses glutamatergic transmission at corticostriatal synapse. Neuropharmacology, 1997 (36), 845-51.
295. Pisani, A; Bernardi, G; Bonsi, P; Centonze, D; Giacomini, P; Calabresi, P. Cell-type specificity of mGluR activation in striatal neuronal subtypes. Amino Acids, 2000 (19), 119-29.